X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1237) 1237
index medicus (1195) 1195
male (932) 932
female (860) 860
middle aged (722) 722
2-pyridinylmethylsulfinylbenzimidazoles (693) 693
lansoprazole (672) 672
adult (643) 643
omeprazole - analogs & derivatives (619) 619
proton pump inhibitors (558) 558
gastroenterology & hepatology (517) 517
aged (505) 505
omeprazole (461) 461
anti-ulcer agents - therapeutic use (375) 375
pharmacology & pharmacy (373) 373
treatment outcome (370) 370
anti-ulcer agents - adverse effects (330) 330
helicobacter infections - drug therapy (329) 329
omeprazole - therapeutic use (319) 319
omeprazole - adverse effects (300) 300
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (287) 287
helicobacter pylori (280) 280
drug therapy, combination (278) 278
2-pyridinylmethylsulfinylbenzimidazoles - adverse effects (276) 276
rabeprazole (262) 262
anti-ulcer agents - administration & dosage (260) 260
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (232) 232
double-blind method (226) 226
gastroesophageal reflux - drug therapy (223) 223
pantoprazole (217) 217
omeprazole - administration & dosage (206) 206
prospective studies (199) 199
benzimidazoles - adverse effects (192) 192
proton pump inhibitor (187) 187
benzimidazoles - therapeutic use (183) 183
adolescent (173) 173
proton pump inhibitors - adverse effects (164) 164
proton pump inhibitors - therapeutic use (156) 156
helicobacter pylori - drug effects (154) 154
aged, 80 and over (150) 150
abridged index medicus (145) 145
dose-response relationship, drug (145) 145
infection (143) 143
drug administration schedule (142) 142
amoxicillin - therapeutic use (139) 139
anti-bacterial agents - therapeutic use (136) 136
benzimidazoles - administration & dosage (134) 134
sulfoxides - adverse effects (134) 134
clarithromycin - therapeutic use (132) 132
time factors (132) 132
amoxicillin - administration & dosage (130) 130
amoxicillin (125) 125
proton pump inhibitors - administration & dosage (125) 125
medicine & public health (124) 124
enzyme inhibitors - adverse effects (122) 122
pharmacokinetics (122) 122
clarithromycin - administration & dosage (120) 120
therapy (118) 118
sulfoxides - therapeutic use (117) 117
clarithromycin (116) 116
drug interactions (115) 115
efficacy (113) 113
anti-bacterial agents - administration & dosage (111) 111
management (108) 108
eradication (107) 107
anti-ulcer agents - pharmacology (103) 103
cross-over studies (100) 100
duodenal ulcer - drug therapy (99) 99
enzyme inhibitors - therapeutic use (98) 98
omeprazole - pharmacology (96) 96
ranitidine (95) 95
follow-up studies (94) 94
double-blind (93) 93
peptic ulcer - drug therapy (93) 93
triple therapy (93) 93
administration, oral (90) 90
medicine, general & internal (90) 90
anti-bacterial agents - adverse effects (89) 89
young adult (89) 89
gastroesophageal-reflux disease (87) 87
gastroenterology (86) 86
sulfoxides - administration & dosage (86) 86
gastroesophageal reflux (84) 84
2-pyridinylmethylsulfinylbenzimidazoles - pharmacology (83) 83
clarithromycin - adverse effects (83) 83
duodenal-ulcer (81) 81
amoxicillin - adverse effects (79) 79
animals (78) 78
esophagitis, peptic - drug therapy (78) 78
metronidazole (78) 78
esophagitis (77) 77
gastroesophageal reflux disease (77) 77
gastric acid - secretion (75) 75
helicobacter infections - microbiology (75) 75
anti-inflammatory agents, non-steroidal - adverse effects (74) 74
internal medicine (74) 74
cytochrome p-450 cyp2c19 (73) 73
metaanalysis (70) 70
risk factors (70) 70
2-pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics (68) 68
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1166) 1166
Japanese (33) 33
German (30) 30
French (16) 16
Spanish (13) 13
Russian (10) 10
Korean (3) 3
Danish (2) 2
Italian (2) 2
Norwegian (2) 2
Polish (2) 2
Chinese (1) 1
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Portuguese (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Pediatrics, The, ISSN 0022-3476, 2013, Volume 163, Issue 3, pp. 686 - 691
Objective To determine whether cytochrome P 450CYP 2C19 haplotype associates with lansoprazole-associated adverse event frequency. Study design Respiratory... 
Pediatrics | Sore throat | Poor metabolizer | SNP | Upper respiratory tract infection | Cytochrome P450 | PPI | CYP | Single nucleotide polymorphism | Extensive metabolizer | Wild type | URI | Proton pump inhibitor | COMMUNITY-ACQUIRED PNEUMONIA | METAANALYSIS | PHARMACOKINETICS | GASTROESOPHAGEAL-REFLUX DISEASE | ACID-SUPPRESSIVE DRUGS | PHARMACOGENOMICS | PROTON PUMP INHIBITORS | RISK | PEDIATRICS | BACTERIAL OVERGROWTH | POORLY CONTROLLED ASTHMA | Haplotypes | Bronchitis - genetics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Genotyping Techniques | Pharyngitis - chemically induced | Respiratory Tract Infections - genetics | Pharyngitis - genetics | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Respiratory Tract Infections - chemically induced | Female | Odds Ratio | Child | Bronchitis - chemically induced | Proton Pump Inhibitors - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Logistic Models | Genetic Markers | Proton Pump Inhibitors - therapeutic use | Asthma - drug therapy | Asthma - genetics | Proton Pump Inhibitors - pharmacokinetics | Cytochrome P-450 CYP2C19 | Adolescent | Polymorphism, Single Nucleotide | Lansoprazole | Complications and side effects | Medical colleges | Pharmacogenetics | Cytochrome P-450 | Drugstores | Genetic aspects | Index Medicus | Abridged Index Medicus
Journal Article
BMC Gastroenterology, ISSN 1471-230X, 03/2013, Volume 13, Issue 1, pp. 56 - 56
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2008, Volume 48, Issue 4, pp. 475 - 484
Journal Article
Journal Article
Helicobacter, ISSN 1083-4389, 04/2013, Volume 18, Issue 2, pp. 129 - 134
Background The eradication of Helicobacter pylori has been always a concern. In the present study, we aimed to compare two novel treatments in Iran. Method... 
hybrid | clarithromycin | sequential | ran | elicobacter pylor | Hybrid | Clarithromycin | Helicobacter pylori | Iran | Sequential | METAANALYSIS | EFFICACY | PROTON-PUMP INHIBITOR | ANTIBIOTIC-RESISTANCE | MICROBIOLOGY | AMOXICILLIN | REGIMENS | TRIPLE THERAPY | INFECTION | 1ST-LINE | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Humans | Middle Aged | Tinidazole - adverse effects | Helicobacter pylori - drug effects | Male | Tinidazole - therapeutic use | Anti-Bacterial Agents - therapeutic use | Peptic Ulcer - microbiology | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Anti-Ulcer Agents - therapeutic use | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Anti-Ulcer Agents - adverse effects | Treatment Outcome | Clarithromycin - therapeutic use | Anti-Ulcer Agents - administration & dosage | Tinidazole - administration & dosage | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Helicobacter Infections - microbiology | Urea | Care and treatment | Amoxicillin | Clinical trials | Helicobacter infections | Comparative analysis | Antiulcer drugs | Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 01/2010, Volume 152, Issue 1, pp. 1 - 9
Journal Article
Stroke, ISSN 0039-2499, 03/2015, Volume 46, Issue 3, pp. 722 - 731
BACKGROUND AND PURPOSE—There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the... 
LANSOPRAZOLE | drug interactions | PROPENSITY SCORE | CARDIOVASCULAR EVENTS | CORONARY | OMEPRAZOLE | stroke | CLINICAL NEUROLOGY | pharmacoepidemiology | proton pump inhibitors | CONCOMITANT USE | platelet aggregation inhibitors | cohort studies | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | OUTCOMES | Medicaid | JAPANESE PATIENTS | ARTERY-DISEASE | Rabeprazole - adverse effects | Esomeprazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Male | Risk | Drug Therapy, Combination - adverse effects | Stroke - chemically induced | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Stroke - epidemiology | Retrospective Studies | Brain Ischemia - chemically induced | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Data Interpretation, Statistical | Stroke - prevention & control | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Proportional Hazards Models | Omeprazole - adverse effects | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Lansoprazole - adverse effects | Aged | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Rabeprazole - administration & dosage | Index Medicus | Pharmacoepidemiology | Stroke | Drug interactions | Cohort studies | Platelet aggregation inhibitors | Proton pump inhibitors
Journal Article
Helicobacter, ISSN 1083-4389, 06/2013, Volume 18, Issue 3, pp. 180 - 186
Background The eradication rate with PPI-based standard triple therapy for Helicobacter pylori infection has fallen considerably. One recent innovation is... 
quadruple | concomitant | Helicobacter pylori | eradication | sequential | Quadruple | Sequential | Eradication | Concomitant | METAANALYSIS | MANAGEMENT | CONSENSUS CONFERENCE | CLARITHROMYCIN RESISTANCE | REGIMEN | MICROBIOLOGY | KOREA | TRIAL | QUADRUPLE THERAPY | TRIPLE THERAPY | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Proton Pump Inhibitors - pharmacology | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Rabeprazole | Anti-Bacterial Agents - therapeutic use | Proton Pump Inhibitors - administration & dosage | Metronidazole - therapeutic use | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Anti-Ulcer Agents - pharmacology | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Anti-Ulcer Agents - therapeutic use | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Breath Tests | Treatment Outcome | Proton Pump Inhibitors - therapeutic use | Pilot Projects | Urea - therapeutic use | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | Aged | Anti-Bacterial Agents - pharmacology | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Helicobacter Infections - microbiology | Urea | Care and treatment | Patient outcomes | Amoxicillin | Helicobacter infections | Index Medicus
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 01/2012, Volume 35, Issue 1, pp. 56 - 65
Background The eradication rates following standard triple therapy for Helicobacter pylori infection are declining worldwide. Recent studies have shown that... 
METAANALYSIS | MANAGEMENT | EFFICACY | ERADICATION RATES | PROTON-PUMP INHIBITOR | KOREAN PATIENTS | PHARMACOLOGY & PHARMACY | QUADRUPLE | GASTROENTEROLOGY & HEPATOLOGY | ANTIMICROBIAL RESISTANCE | FAILURE | CONSENSUS REPORT | Humans | Middle Aged | Male | Rabeprazole | Peptic Ulcer - microbiology | Time Factors | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Republic of Korea | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Endoscopy, Gastrointestinal | Treatment Outcome | Anti-Ulcer Agents - administration & dosage | Amoxicillin - adverse effects | Aged | Helicobacter pylori - isolation & purification | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Helicobacter Infections - microbiology | Medical colleges | Medical research | Clinical trials | Standards | Helicobacter pylori | Amoxicillin | Medicine, Experimental | Medical care | Helicobacter infections | Comparative analysis | Health aspects | Quality management | Infection | Clarithromycin | Hospitals | Metronidazole | Index Medicus
Journal Article
Helicobacter, ISSN 1083-4389, 08/2018, Volume 23, Issue 4, pp. e12498 - n/a
BackgroundBismuth quadruple therapy is the treatment of choice for the first-line therapy of Helicobacter pylori infection in areas of high clarithromycin... 
Proteobacteria | Helicobacter pylori | microbiome | bismuth quadruple therapy | dysbiosis | CLARITHROMYCIN | OMEPRAZOLE | PROBIOTICS | MICROBIOLOGY | RANDOMIZED CONTROLLED-TRIAL | AMOXICILLIN | SUPPLEMENTATION | PROTON PUMP INHIBITOR | TRIPLE-THERAPY | TETRACYCLINE | METRONIDAZOLE | GASTROENTEROLOGY & HEPATOLOGY | Dysbiosis - etiology | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Bismuth - therapeutic use | Bismuth - adverse effects | Dysbiosis - microbiology | Proteobacteria - genetics | Young Adult | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Drug Therapy, Combination - adverse effects | Metronidazole - therapeutic use | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Helicobacter Infections - drug therapy | Actinobacteria - genetics | Metronidazole - adverse effects | Adult | Female | Actinobacteria - isolation & purification | Anti-Bacterial Agents - adverse effects | Bacteroidetes - isolation & purification | Proton Pump Inhibitors - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Tetracycline - therapeutic use | Tetracycline - adverse effects | Proton Pump Inhibitors - therapeutic use | Gastrointestinal Microbiome - drug effects | Proteobacteria - isolation & purification | Actinobacteria - growth & development | Bacteroidetes - growth & development | Helicobacter pylori - physiology | Proteobacteria - growth & development | Bacteroidetes - genetics | Helicobacter Infections - microbiology | Microbiota (Symbiotic organisms) | RNA | Analysis | Helicobacter infections | Antibacterial agents | Antiulcer drugs | Therapy | Data analysis | Dysbacteriosis | Clarithromycin | rRNA 16S | Data processing | Abundance | Nucleic acids | Patients | Gastritis | Polymerase chain reaction | Side effects | Microbiota | Cyanobacteria | Relative abundance | Bismuth | Impact resistance | Index Medicus
Journal Article